Company Overview
| Stock Name | Arrail Group |
|---|---|
| Stock Code | 06639 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 中國領先的口腔醫療服務集團,運營瑞爾齒科(高端)和瑞泰口腔(中端)品牌,提供普通牙科、正畸科及種植科等專業及個性化口腔醫療服務。 |
| Listing Date | 2022-03-22 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市朝陽區朝來高科技產業園紫月路18號院11號樓6層 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號大新金融中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.arrailgroup.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 14.62 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 7,310 |
| Par Value | To be extracted |
| Offer Period | 2022-03-09 to 2022-03-14 |
| Global Offering Shares | 46,527,500 shares |
| HK Public Offer Shares (Initial) | 4,653,000 shares (10.0%) |
| Public Offer Lots (Initial) | 9,306lots (Pool A4,653lots,Pool B4,653lots) |
| International Placing Shares (Initial) | 41,874,500 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 581,591,950 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 74.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 680,232,050 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 7,310 |
| 2 lots | 1,000 | HK$ 14,620 |
| 3 lots | 1,500 | HK$ 21,930 |
| 4 lots | 2,000 | HK$ 29,240 |
| 5 lots | 2,500 | HK$ 36,550 |
| 6 lots | 3,000 | HK$ 43,860 |
| 7 lots | 3,500 | HK$ 51,170 |
| 8 lots | 4,000 | HK$ 58,480 |
| 9 lots | 4,500 | HK$ 65,790 |
| 10 lots | 5,000 | HK$ 73,100 |
| 12 lots | 6,000 | HK$ 87,720 |
| 14 lots | 7,000 | HK$ 102,340 |
| 16 lots | 8,000 | HK$ 116,960 |
| 18 lots | 9,000 | HK$ 131,580 |
| 20 lots | 10,000 | HK$ 146,200 |
| 30 lots | 15,000 | HK$ 219,300 |
| 40 lots | 20,000 | HK$ 292,400 |
| 50 lots | 25,000 | HK$ 365,500 |
| 60 lots | 30,000 | HK$ 438,600 |
| 70 lots | 35,000 | HK$ 511,700 |
| 90 lots | 45,000 | HK$ 657,900 |
| 100 lots | 50,000 | HK$ 731,000 |
| 120 lots | 60,000 | HK$ 877,200 |
| 140 lots | 70,000 | HK$ 1,023,400 |
| 160 lots | 80,000 | HK$ 1,169,600 |
| 180 lots | 90,000 | HK$ 1,315,800 |
| 200 lots | 100,000 | HK$ 1,462,000 |
| 400 lots | 200,000 | HK$ 2,924,000 |
| 600 lots | 300,000 | HK$ 4,386,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 800 lots | 400,000 | HK$ 5,848,000 |
| 1,400 lots | 700,000 | HK$ 10,234,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 1.03B |
| Est. Threshold | HK$ 9.73B |
| Analysis Result | HK market cap below threshold, need +846% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 8,502,874,309 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣597.8百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 90,332,050 |
| Listing Expenses / Funds Raised | ~13.28% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019-03 | 2020-03 | 2021-03 |
|---|---|---|---|
| Revenue | 1,080,291 | 1,099,868 | 1,515,127 |
| Cost of sales | -916,519 | -988,477 | -1,150,707 |
| Gross profit | 163,772 | 111,391 | 364,420 |
| Other income and gains, net | -4,468 | -3,129 | 2,286 |
| Selling and distribution expenses | -105,576 | -84,825 | -79,122 |
| Administrative expenses | -103,878 | -112,680 | -130,330 |
| Operating profit | -84,043 | -133,444 | 124,467 |
| Net finance costs | -28,662 | -38,685 | -44,333 |
| Share of associates and JVs | -9,939 | -2,716 | 2,602 |
| Profit before tax | -315,462 | -320,894 | -581,744 |
| Income tax expense | 11,293 | -4,931 | -16,018 |
| Profit for the year | -304,169 | -325,825 | -597,762 |
| Profit attributable to owners | -301,178 | -316,854 | -599,420 |
Balance Sheet
| Item | 2019-03 | 2020-03 | 2021-03 | 2021-09 |
|---|---|---|---|---|
| Cash and cash equivalents | 168,457 | 172,618 | 676,304 | |
| Trade and bills receivables | 111,745 | 105,017 | 155,935 | |
| Inventories | 38,455 | 37,500 | 39,036 | |
| Total current assets | 586,785 | 620,118 | 1,092,961 | |
| Total assets | 1,875,736 | 1,902,991 | 2,350,754 | |
| Total current liabilities | 740,290 | 3,370,364 | 4,257,453 | |
| Total liabilities | 3,512,269 | 3,931,094 | 4,807,331 | |
| Total equity | -1,636,533 | -2,028,103 | -2,456,577 | |
| Equity attributable to owners | -1,678,334 | -2,064,767 | -2,499,872 | |
| Interest-bearing borrowings | 446,968 | 520,870 | 489,291 | 514,384 |
Cash Flow Statement
| Item | 2019-03 | 2020-03 | 2021-03 | 2021-09 |
|---|---|---|---|---|
| Net cash from operating activities | 136,809 | 154,294 | 242,870 | |
| Net cash from investing activities | -309,309 | -109,594 | 61,753 | |
| Net cash from financing activities | 34,444 | -43,847 | 217,513 | |
| Net increase in cash | -138,056 | 853 | 522,136 | |
| Purchase of PP&E | -184,020 | -289,110 | -1,134,830 | -40,150 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 13.8 |
|---|---|
| First Day Open | HK$ 14.6 |
| First Day Change | -5.61% |
| First Day Volume | 6072000.0 |
| First Day Turnover | 84333900.0 |
| Use of Proceeds | 1、約75%(或442.4百萬港元)將用于業務擴張、在現有及新城市開設新的瑞爾齒科和瑞泰口腔的醫院及診所;
2、約15%(或88.5百萬港元)將用于建設及優化我們的信息技術基礎設施;
3、約10%(或59.0百萬港元)將用作營運資金,以繼續為客戶提供優質的口腔醫療服務,通過采取以下舉措。 |
Underwriting Syndicate
Overall Coordinators (4)
Joint Bookrunners (7)
Joint Lead Managers (7)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Abax Asian Structured Private Credit Fund III, LP | 195,330,510 HKD | — | 28.72% | — | 6 months | 2022-09-22 |
| 2 | Harvest International Premium Value (Secondary Market) Fund SPC | 156,258,560 HKD | — | 22.97% | — | 6 months | 2022-09-22 |
| 3 | Hudson Bay Master Fund LTD | 78,129,280 HKD | — | 11.49% | — | 6 months | 2022-09-22 |
| 4 | OrbiMed Funds | 39,064,640 HKD | — | 5.74% | — | 6 months | 2022-09-22 |
| 5 | 高鹏(香港)有限公司 | 39,064,640 HKD | — | 5.74% | — | 6 months | 2022-09-22 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 鄒其芳 | — |
| Company Secretary | 王承鏱 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 鄒其芳先生透過Rise Day Holdings Limited、Mingda International Limited、Beier Holdings Limited及ESOP BVI持有本公司約31.55%權益,為控股股東;其他主要股東包括Elbrus Investments Pte. Ltd.(10.01%)、Total Success Investment Ltd.(9.50%)、Broad Street Investments Holding (Singapore) Pte. Ltd.(6.31%)、KPCB China Fund, L.P.(5.40%)、HH AGL Holdings Limited(4.72%)等。 |
|---|




